Search results
Results from the WOW.Com Content Network
Common side effects include bone marrow suppression, liver and kidney problems, nausea, fever, rash, shortness of breath, mouth sores, diarrhea, neuropathy, and hair loss. [2] Use during pregnancy will likely result in fetal harm. [2] Gemcitabine is in the nucleoside analog family of medication. [2]
In the United Kingdom, the National Institute for Health and Care Excellence (NICE), in a draft guidance issued in 2014, rejected the use of Abraxane in treatment due to concerns of side effects, efficacy, and cost relative to Gemzar (gemcitabine). [10] However, on 18 May 2017 NICE issued a reappraisal for the use of Abraxane in the UK.
It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".
ABRAXANE ® Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly ...
The most common grade 3 or 4 adverse events in MPACT for ABRAXANE plus gemcitabine versus gemcitabine alone were neutropenia (38% vs. 27%, respectively), fatigue (17% vs. 7%) and peripheral ...
Shares of Threshold Pharmaceuticals popped nearly 8% in early trading today on the phase 3 initiation announcement for pancreatic cancer drug TH-302. While a licensing agreement put the trial ...
A number of these side effects are associated with the excipient used, Cremophor EL, a polyoxyethylated castor oil. Allergies to cyclosporine , teniposide , and other drugs delivered in polyoxyethylated castor oil may increase the risk of adverse reactions to paclitaxel.
Ho-hum for AbraxaneFindings from a phase 3 study of Abraxane. Celgene was one of several companies presenting at the American Society of Clinical Oncology, or ASCO, annual meeting in Chicago this ...